Premium
The effect of physiological concentrations of six hormones on the growth of breast and prostate cell lines treated with human serum
Author(s) -
Esfahani Amin,
Bashyam Balachandran,
Kendall Cyril WC,
Srichaikul Korbua,
Archer Michael C,
Jenkins David JA
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.207.3
Subject(s) - lncap , endocrinology , medicine , dihydrotestosterone , testosterone (patch) , hormone , cell growth , glucagon , prostate cancer , chemistry , prostate , insulin , biology , androgen , cancer , biochemistry
Background The majority of cell culture studies assess the effect of hormones on cancer cell growth using media supplemented with charcoal treated serum (CTS). Our objective was to determine the effect of various hormones on the growth of breast and prostate cancer cells incubated in untreated whole human serum (PHS). Methods MCF‐7, MCF‐10A breast and LNCaP prostate cancer cell lines supplemented with PHS were treated with two physiological concentrations of six hormones (17β‐estradiol (E2), dehydroepiandosterone (DHEA), dihydrotestosterone (DHT), testosterone (T), insulin and glucagon). Cell viability was measured after 72 hours using the MTS assay. Results All hormones stimulated growth of MCF‐7 cells (p<0.05). MCF‐10A cell growth was inhibited by DHEA, DHT and T (p<0.05), unaffected by E2 and glucagon, and stimulated by insulin (p<0.05). LNCaP cell growth was stimulated by the highest concentration of DHEA and DHT (p<0.05) and inhibited by the highest concentration of E2 (p<0.05). Insulin and T did not alter LNCaP growth. PHS lowered the magnitude of the hormonal effect by comparison to CTS. Conclusions Unexpectedly, high concentrations of testosterone did not stimulate LNCaP cell growth and we observed for the first time that glucagon stimulates breast cancer cell growth. (Funding provided by Canada Research Chair discretionary funds)